Quick Takeaways:
- Endovia Health Sciences & Lupvindol BioSciences announced that the FDA’s Center for Veterinary Medicine has designated CannEpil, an investigational CBD/THC oral solution for bone cancer-related pain in dogs, as a minor use under the MUMS program.
- The designation makes CannEpil eligible to pursue the FDA’s conditional approval pathway, while Endovia and Lupvindol prepare for a November 19, 2026, FDA Pre-Submission Conference covering development studies, manufacturing and regulatory requirements.
- The companies are also establishing U.S.-based, FDA-compliant manufacturing capabilities to support clinical and regulatory development and, subject to approval, a potential 2027 veterinary launch.
Why It Matters?
CannEpil’s MUMS designation could give Endovia and Lupvindol an early-mover advantage in veterinary oncology pain management, particularly if the conditional pathway enables faster commercialization. A potential 2027 launch may expand cannabinoid-based treatment options for dogs while creating competitive pressure in the underserved market for cancer-related pain therapies.
Source: Globenewswire
